Halozyme Therapeutics Inc Quick Ratio (HALO) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Halozyme Therapeutics Inc   (NASDAQ: HALO)

Halozyme Therapeutics Inc 's Quick Ratio

HALO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.61 below Halozyme Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 121 other companies have achieved higher Quick Ratio than Halozyme Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2156, from total ranking in the first quarter 2026 at 2751.

Explain Quick Ratio?
How much Cash & cash equivalents HALO´s has?
What are HALO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HALO Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 179.98 % 141.53 % 27.31 % 669.4 % 0.69 %
Y / Y Cash & cash equivalent Change 273.55 % 75.67 % 15.51 % 171.95 % -67.07 %
Quick Ratio MRQ 0.61 0.85 0.76 0.5 0.46
HALO's Total Ranking # 2156 # 2751 # 3047 # 3230 # 2183
Seq. Current Liabilities Change 3.51 % 105.1 % -78.85 % 523.48 % -10.7 %
Seq. Cash & cash equivalent Change -25.4 % 131.47 % -68.11 % 578.4 % -64.92 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 122
Healthcare Sector # 714
Overall Market # 2433


Quick Ratio Statistics
High Average Low
15.22 3.72 0.46
(Jun 30 2020)   (Jun 30 2025)




Financial Statements
Halozyme Therapeutics Inc 's Current Liabilities $ 376 Millions Visit HALO's Balance sheet
Halozyme Therapeutics Inc 's Cash & cash equivalent $ 231 Millions Visit HALO's Balance sheet
Source of HALO's Sales Visit HALO's Sales by Geography


Cumulative Halozyme Therapeutics Inc 's Quick Ratio

HALO's Quick Ratio for the trailling 12 Months

HALO Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 229.25 % 184.36 % 153.26 % 148.12 % 3.49 %
Y / Y Cash & cash equivalent TTM Growth 115.27 % 45.83 % 27.14 % 23.76 % -31.77 %
Quick Ratio TTM 0.62 0.61 0.61 0.61 0.95
Total Ranking TTM # 1772 # 2074 # 1562 # 1181 # 1010
Seq. Current Liabilities TTM Growth 15.99 % 16.38 % 3.01 % 136.77 % 0.17 %
Seq. Cash & cash equivalent TTM Growth 18.29 % 16.85 % 2.32 % 52.2 % -19.86 %

Quick ratio ranking by company, industry and sector >> Back to HALO Financial Strength Comparisons >> Go to Compare HALO Quick Ratio to its Competitors

On the trailing twelve months basis HALO Cash & cash equivalent more than doubled by 273.55 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Halozyme Therapeutics Inc 's Quick Ratio to 0.62, Quick Ratio remained below HALO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Halozyme Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3147.

Explain Quick Ratio?
How much Cash & cash equivalents HALO´s has?
What are HALO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 900
Within the Market # 2156


trailing twelve months Quick Ratio Statistics
High Average Low
5.58 1.58 0.41
(Dec 31 2012)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions
Senti Biosciences Holdings Inc   0.83 $ 13.124  Millions$ 15.765  Millions
Pelthos Therapeutics Inc   0.78 $ 24.776  Millions$ 31.959  Millions
Ocugen Inc   0.75 $ 100.051  Millions$ 133.080  Millions
Sab Biotherapeutics Inc   0.71 $ 8.267  Millions$ 11.705  Millions
Vaxcyte Inc   0.68 $ 183.190  Millions$ 271.277  Millions
Halozyme Therapeutics Inc   0.61 $ 231.081  Millions$ 375.965  Millions
Silexion Therapeutics Corp  0.57 $ 2.258  Millions$ 3.976  Millions
Atlantic Coastal Acquisition Corp Ii  0.52 $ 4.291  Millions$ 8.225  Millions
Surrozen Inc   0.50 $ 102.039  Millions$ 203.292  Millions
Pluri Inc   0.40 $ 13.126  Millions$ 32.719  Millions
Outlook Therapeutics Inc   0.39 $ 11.242  Millions$ 28.679  Millions
Neurocrine Biosciences Inc   0.37 $ 390.500  Millions$ 1,046.100  Millions
Curis Inc   0.37 $ 5.100  Millions$ 13.675  Millions
Creative Medical Technology Holdings Inc   0.36 $ 0.250  Millions$ 0.699  Millions

Date modified: 2026-09-12T06:14:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.